Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients

被引：36

作者：

Moya, Patricia ^{[1
,2
]}

Salazar, Juliana ^{[3
,4
]}

Jesus Arranz, Mara ^{[5
]}

Diaz-Torne, Cesar ^{[1
]}

del Rio, Elisabeth ^{[3
]}

Casademont, Jordi ^{[1
]}

Corominas, Hector ^{[6
]}

Baiget, Montserrat ^{[3
,4
]}

机构：

[1] Hosp Santa Creu & St Pablo, Dept Internal Med, Barcelona, Spain

[2] Univ Autonoma Barcelona, Fac Med, E-08193 Barcelona, Spain

[3] Hosp Santa Creu & St Pablo, Dept Genet, Barcelona, Spain

[4] ISCIII Ctr Biomed Res Rare Dis CIBERER, U705, Madrid, Spain

[5] Fundacio Docencia & Recerca Mutua Terrassa, Terrassa, Spain

[6] Hosp Moises Broggi, Dept Rheumatol, Barcelona, Spain

来源：

PHARMACOGENOMICS | 2016年 / 17卷 / 01期

关键词：

ABCB1; FPGS; GGH; methotrexate; pharmacogenetics; rheumatoid arthritis; SLC19A1/RFC1; SINGLE-NUCLEOTIDE POLYMORPHISMS; EULAR RECOMMENDATIONS; AMERICAN-COLLEGE; TOXICITY; PATHWAY; MANAGEMENT; EFFICACY; MONOTHERAPY; POPULATION; TRANSPORT;

D O I：

10.2217/pgs.15.150

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Methotrexate (MTX) is the most used drug for the treatment of rheumatoid arthritis (RA) although outcome differs among patients. Aim: To evaluate whether polymorphisms in pharmacokinetic genes are associated with outcome in RA patients receiving MTX. Patients & methods: We analyzed 28 SNPs in SLC19A1/RFC1, ABCB1, FPGS and GGH genes. Results: We studied 194 RA patients receiving MTX monotherapy. Two FPGS SNPs, rs10987742 and rs10106, were associated with response (p = 0.033 and p = 0.041, respectively). The FPGS rs10106 variant was also associated with MTX survival (p = 0.005) and toxicity (p = 0.021). Three ABCB1 SNPs, rs868755, rs10280623 and rs1858923, were associated with toxicity (p = 0.025, p = 0.048 and p = 0.031, respectively). Conclusion: FPGS and ABCB1 genetic variants can influence the outcome in RA patients receiving MTX monotherapy.

引用

页码：11 / 25

页数：15

共 41 条

[1] Early rheumatoid arthritis:: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy [J].

Alarcón, GS .

NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2006, 2 (06) :296-297

[2]

Albrecht K, 2010, CLIN EXP RHEUMATOL, V28, pS95

[3]

Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100

[4]

Aletaha D, 2002, RHEUMATOLOGY, V41, P1367

[5]

Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]

[6] Annotation of functional variation in personal genomes using RegulomeDB [J].

Boyle, Alan P. ;

Hong, Eurie L. ;

Hariharan, Manoj ;

Cheng, Yong ;

Schaub, Marc A. ;

Kasowski, Maya ;

Karczewski, Konrad J. ;

Park, Julie ;

Hitz, Benjamin C. ;

Weng, Shuai ;

Cherry, J. Michael ;

Snyder, Michael .

GENOME RESEARCH, 2012, 22 (09) :1790-1797

[7]

Chan ESL, 2013, BULL HOSP JT DIS, V71, pS5

[8] EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) [J].

Combe, B. ;

Landewe, R. ;

Lukas, C. ;

Bolosiu, H. D. ;

Breedveld, F. ;

Dougados, M. ;

Emery, P. ;

Ferraccioli, G. ;

Hazes, J. M. W. ;

Klareskog, L. ;

Machold, K. ;

Martin-Mola, E. ;

Nielsen, H. ;

Silman, A. ;

Smolen, J. ;

Yazici, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) :34-45

[9] Pharmacogenetic Polymorphisms Contributing to Toxicity Induced by Methotrexate in the Southern Spanish Population with Rheumatoid Arthritis [J].

Cristian Plaza-Plaza, Jose ;

Aguilera, Margarita ;

Canadas-Garre, Marisa ;

Chemello, Clarice ;

Gonzalez-Utrilla, Alfonso ;

Faus Dader, Maria Jose ;

Angel Calleja, Miguel .

OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, 2012, 16 (11) :589-595

[10]

Davis LA, 2014, CLIN EXP RHEUMATOL, V32, P324

← 1 2 3 4 5 →